2X Blend Tesamorelin / Ipamorelin

Description

Tesamorelin / Ipamorelin Blend Technical Overview

2X Blend Tesamorelin / Ipamorelin is a dual-compound research formulation combining a synthetic GHRH analogue with a growth hormone secretagogue receptor agonist.

Tesamorelin interacts with GHRHR, while Ipamorelin acts through GHS-R1a. These receptor systems participate in distinct mechanisms of endocrine signaling.

The compounds have been investigated independently. Their combined biological activity, compatibility, and stability cannot be established from separate studies alone.

Compound Specifications

Storage and Handling

• Follow storage recommendations for the complete formulation.
• Protect from contamination and degradation.
• Evaluate mixture compatibility separately.

Lyophilized Format

The blend may be supplied in lyophilized form. Physical characteristics depend on manufacturing conditions.

Research Use Disclaimer

This blend is not represented as an FDA-approved pharmaceutical product and is not intended for human or veterinary administration.

Frequently Asked Questions

What Does the Blend Contain?

Tesamorelin and Ipamorelin.

What Is the Tesamorelin Target?

GHRHR.

What Is the Ipamorelin Target?

GHS-R1a.

Does 2X Identify the Dosage?

No specific concentration or vial content can be derived from the name alone.

Research Overview

Research on the individual compounds involves two distinct endocrine receptor pathways.

GHRHR Research

Tesamorelin-associated receptor signaling can be investigated in cellular systems.

GHS-R1a Research

Ipamorelin-associated receptor activation can be evaluated separately.

Combination Research

Mixed formulations require independent assessment of stability and cellular effects.

Research Applications

References

1. Research on Tesamorelin and Ipamorelin — PubMed.

Certificate of Analysis (COA)

Documentation should establish both molecular identities, individual component amounts, purity, and blend stability.

Peptide Lives